Multicenter, Prospective, Non-interventional Study "Sorafenib as Neoadjuvant Therapy Before Cytoreductive Nephrectomy in Patients With Metastatic Renal Cell Carcinoma"
Phase of Trial: Phase IV
Latest Information Update: 09 Feb 2018
Price : $35 *
At a glance
- Drugs Sorafenib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms SANE
- Sponsors Bayer
- 06 Feb 2018 Status changed from active, no longer recruiting to completed.
- 21 Nov 2017 Planned End Date changed from 31 Aug 2017 to 30 Nov 2017.
- 18 Aug 2017 Planned End Date changed from 31 May 2017 to 31 Aug 2017.